Clinical Trials

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

30 enrolled

Breast Neoplasms

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

435 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT04116541 2025-11-21

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

190 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

930 enrolled

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

200 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT06953882 2025-07-14

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Phase EARLY_PHASE1 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT06959979 2025-05-07

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

60 enrolled

CNS

Medulloblastoma

NCT04315233 2025-04-22

CHARGE

34 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05296746 2025-03-18

RIBOLARIS

1,100 enrolled

Breast Neoplasms

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

202 enrolled

Breast Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05452213 2023-04-18

CAPTOR-BC

Phase 4 Recruiting

1,000 enrolled

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

60 enrolled